Mnemonic

Clearance and Half-Life

A memory aid for the relationship between clearance, volume and half-life.

Expansion

Half-life depends on both clearance and volume of distribution

Mnemonic

Three equations that connect:

  • Half life = 0.693 x Vd / clearance
  • Loading dose = Vd x target concentration
  • Maintenance dose = clearance x target concentration

“Loading depends on volume, maintenance depends on clearance.” That single distinction explains why a loading dose is unchanged in renal failure while the maintenance dose must be reduced.

Steady state takes 4 to 5 half lives, whatever the dose, which is why a loading dose is used when the effect is needed sooner, as with digoxin, amiodarone and phenytoin.

First order kinetics means a constant proportion is cleared per unit time, so half life is constant. Zero order means a constant amount, because the enzymes are saturated, so small dose increases cause large concentration rises. The classic zero order drugs are phenytoin, ethanol, aspirin in overdose and theophylline.

Expansion

Half-life = (0.693 x volume of distribution) / clearance

So a long half-life can result from either low clearance or a large volume of distribution, which is why amiodarone has a half-life of about 50 days despite normal hepatic function.

Clearance determines the maintenance dose; volume of distribution determines the loading dose.

Time course

  • Steady state after about 5 half-lives, whatever the dose
  • 95 per cent eliminated after 5 half-lives from stopping
  • A loading dose shortcuts the wait, which is why it is used for amiodarone, digoxin and phenytoin when a rapid effect is needed

Clinical consequences

  • Changing a dose requires 5 half-lives before the new steady state can be judged, which is why thyroxine is rechecked at 6 weeks and warfarin more frequently only because its effect is monitored directly
  • Renal or hepatic impairment reduces clearance, prolonging half-life and requiring dose or interval adjustment
  • Drugs with short half-lives need frequent dosing or modified release formulations